Clinical trial
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects…
NCT00479557 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00479557 |
|---|---|
| Title | Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease |
| Official title | A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Biological, Drug |
| Interventions | ACC-001 + QS-21, ACC-001, QS-21, Placebo: Phosphate buffered saline |
| Enrollment | 86 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | May 28, 2007 |
| Last update posted | Jan 1, 2016 |
| Countries | France, Germany, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: